HTG Molecular Diagnostics to Announce Q1 2022 Financial Results and Host Conference Call on Thursday, May 12

Rhea-AI Summary

HTG Molecular Diagnostics (Nasdaq: HTGM) will release its financial results for Q1 2022 on May 12, 2022, after market close. A conference call is scheduled for 4:30 PM ET to discuss the results and provide a corporate update. HTG focuses on advancing precision medicine through transcriptome-wide profiling, aiding translational research, clinical diagnostics, and targeted therapeutics. Its proprietary RNA platform aims to revolutionize drug discovery and diagnostics across various disease areas.

Positive

• HTG is advancing precision medicine, which may lead to significant market opportunities.
• The company has established partnerships with biopharma leaders and academic institutions, enhancing its credibility.

Negative

• None.

TUCSON, Ariz., May 05, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that it will report its financial results for the quarter ended March 31, 2022 after the market close on Thursday, May 12, 2022.

Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time. Details for the conference call are as follows:

Conference Call & Webcast Details
Date:	Thursday, May 12
Time:	4:30pm ET
Toll Free:	1-855-327-6837
International:	1-631-891-4304
Conference ID:	10019008
Webcast:	https://services.choruscall.com/mediaframe/webcast.html?webcastid=zldEP8Ko

About HTG:

HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, clinical diagnostics and targeted therapeutics across a variety of disease areas.

Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. For more information visit www.htgmolecular.com.

HTG Investor Contact:                

Ashley Robinson                        
LifeSci Advisors                         
Phone: (617) 430-7577                
Email: arr@lifesciadvisors.com        

FAQ

When will HTG Molecular Diagnostics report its Q1 2022 financial results?

HTG will report its Q1 2022 financial results on May 12, 2022.

What time is the HTG conference call for investors regarding financial results?

The conference call will take place at 4:30 PM ET on May 12, 2022.

What is the focus of HTG Molecular Diagnostics?

HTG focuses on advancing precision medicine through transcriptome-wide profiling.

How can investors access the HTG conference call?

Investors can access the conference call via the provided toll-free number or through the webcast link.

What technologies does HTG use in its operations?

HTG utilizes proprietary RNA platform technologies for clinical diagnostics and therapeutic development.